🚨 BREAKTHROUGH: Doctors in Houston Report Complete Disappearance of Aggressive Liver Cancer in a 3-Year-Old Using a Personalized Immunotherapy Made From the Child’s Own Cells No Cancer Detected One Year Late
November 4, 2026 at 1:18 PM
🚨 BREAKTHROUGH: Doctors in Houston Report Complete Disappearance of Aggressive Liver Cancer in a 3-Year-Old Using a Personalized Immunotherapy Made From the Child’s Own Cells No Cancer Detected One Year Late
It turns out that chemotherapy and immunotherapy can actually reinforce each other, but you have to get the timing right:
Chemotherapy Actually Helps Immunotherapy in Cancer
www.science.org
November 3, 2026 at 8:11 PM
It turns out that chemotherapy and immunotherapy can actually reinforce each other, but you have to get the timing right:
ICU admissions in the last year. Immunotherapy has kept me alive and controlled the cancer. But if I continue, I risk potential further toxicity from immunotherapy while I'm recovering from surgery, pneumonia and persistent atrial fibrillation. I want to avoid putting my body through another...
November 5, 2026 at 12:14 PM
ICU admissions in the last year. Immunotherapy has kept me alive and controlled the cancer. But if I continue, I risk potential further toxicity from immunotherapy while I'm recovering from surgery, pneumonia and persistent atrial fibrillation. I want to avoid putting my body through another...
Second immunotherapy, completed it mate.
Now to restart in 6 months time
Now to restart in 6 months time
November 2, 2026 at 5:08 PM
Second immunotherapy, completed it mate.
Now to restart in 6 months time
Now to restart in 6 months time
🧬 Can a #faecaltransplant restore the effectiveness of #immunotherapy for #livercancer?
An interdisciplinary research team led by #MedUniVienna study investigated whether the transfer of #gutbacteria can help when immunotherapy is no longer effective.
📰 @natcomms.nature.com
Read more! ⬇️
An interdisciplinary research team led by #MedUniVienna study investigated whether the transfer of #gutbacteria can help when immunotherapy is no longer effective.
📰 @natcomms.nature.com
Read more! ⬇️
Liver cancer: Faecal microbiota transplantation may enable a response to immunotherapy
Further details!
www.meduniwien.ac.at
November 4, 2026 at 12:29 PM
🧬 Can a #faecaltransplant restore the effectiveness of #immunotherapy for #livercancer?
An interdisciplinary research team led by #MedUniVienna study investigated whether the transfer of #gutbacteria can help when immunotherapy is no longer effective.
📰 @natcomms.nature.com
Read more! ⬇️
An interdisciplinary research team led by #MedUniVienna study investigated whether the transfer of #gutbacteria can help when immunotherapy is no longer effective.
📰 @natcomms.nature.com
Read more! ⬇️
My husband @jebushchrist.bsky.social is doing his last immunotherapy treatment today and is still cancer free and he had probably <5% chance making it 5 years before this new chemo came out 2 years ago. I am SO EXCITED about the future of cancer treatments.
November 4, 2026 at 2:51 PM
My husband @jebushchrist.bsky.social is doing his last immunotherapy treatment today and is still cancer free and he had probably <5% chance making it 5 years before this new chemo came out 2 years ago. I am SO EXCITED about the future of cancer treatments.
Someone nominate Professor Long for the Nobel Prize in Medicine. She's earned it IMO. www.sydney.edu.au/news-opinion... #Nobel #Melanoma
World-first personalised therapeutic cancer vaccine cuts risk of melanoma recurrence
In a world-first international trial, adding a type of personalised therapeutic cancer vaccine made from an individual patient’s own tumours to immunotherapy after surgery for high-risk melanoma, redu...
www.sydney.edu.au
November 5, 2026 at 12:25 AM
Someone nominate Professor Long for the Nobel Prize in Medicine. She's earned it IMO. www.sydney.edu.au/news-opinion... #Nobel #Melanoma
So, I have a very significant decision to make. I haven't had my immunotherapy treatment for a few months now because of major surgery. The funding for this runs out soon and the rules are I'm not allowed to reapply. An additional problem is whether it is medically safe for me to resume as two...
November 5, 2026 at 12:12 PM
So, I have a very significant decision to make. I haven't had my immunotherapy treatment for a few months now because of major surgery. The funding for this runs out soon and the rules are I'm not allowed to reapply. An additional problem is whether it is medically safe for me to resume as two...
hringdi endurtekið í deildina og náði að koma öllu á hreint og held planinu sem að var fyrirætlað!
svo jeij fer ekki aftur í 'chemotherapy'
í staðin fæ ég öruglega að byrja á 'immunotherapy' á afmælisdaginn minn, enn sú veisla!
svo jeij fer ekki aftur í 'chemotherapy'
í staðin fæ ég öruglega að byrja á 'immunotherapy' á afmælisdaginn minn, enn sú veisla!
November 4, 2026 at 4:14 PM
hringdi endurtekið í deildina og náði að koma öllu á hreint og held planinu sem að var fyrirætlað!
svo jeij fer ekki aftur í 'chemotherapy'
í staðin fæ ég öruglega að byrja á 'immunotherapy' á afmælisdaginn minn, enn sú veisla!
svo jeij fer ekki aftur í 'chemotherapy'
í staðin fæ ég öruglega að byrja á 'immunotherapy' á afmælisdaginn minn, enn sú veisla!
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
November 2, 2026 at 5:02 PM
A personalized cancer vaccine from Moderna called Intismeran (also known as mRNA-1457) used in combination with Merck’s cancer immunotherapy Keytruda shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The mRNA-based vaccine was tested
I did immunotherapy, too. It’s real love
November 5, 2026 at 6:22 PM
I did immunotherapy, too. It’s real love
California voters, who rejected a wealth tax, have supported an $8.4 billion bonds to fund immunology and immunotherapy research that is basically a direct benefit to one center in UCLA. A curious way to counter federal research cuts.
November 4, 2026 at 5:31 PM
California voters, who rejected a wealth tax, have supported an $8.4 billion bonds to fund immunology and immunotherapy research that is basically a direct benefit to one center in UCLA. A curious way to counter federal research cuts.
🚀 Cancer immunotherapy is getting smarter and more precise.
At #FallingWalls2026, Christian Seitz (DKTK), Larysa Baraban (HZDR) and Amy Lin (ARPA-H) discuss how to steer immune cells against cancer and monitor their effects in real time.
👉 t1p.de/vuze8
#CancerResearch #Immunotherapy #DZG
At #FallingWalls2026, Christian Seitz (DKTK), Larysa Baraban (HZDR) and Amy Lin (ARPA-H) discuss how to steer immune cells against cancer and monitor their effects in real time.
👉 t1p.de/vuze8
#CancerResearch #Immunotherapy #DZG
November 6, 2026 at 11:33 AM
🚀 Cancer immunotherapy is getting smarter and more precise.
At #FallingWalls2026, Christian Seitz (DKTK), Larysa Baraban (HZDR) and Amy Lin (ARPA-H) discuss how to steer immune cells against cancer and monitor their effects in real time.
👉 t1p.de/vuze8
#CancerResearch #Immunotherapy #DZG
At #FallingWalls2026, Christian Seitz (DKTK), Larysa Baraban (HZDR) and Amy Lin (ARPA-H) discuss how to steer immune cells against cancer and monitor their effects in real time.
👉 t1p.de/vuze8
#CancerResearch #Immunotherapy #DZG
My first immunotherapy visit, in the company of Becky Chambers’ The Long Way to a Small Angry Planet. Science-fictional reading during a treatment that would have been science fiction ten years ago.
November 2, 2026 at 5:17 PM
My first immunotherapy visit, in the company of Becky Chambers’ The Long Way to a Small Angry Planet. Science-fictional reading during a treatment that would have been science fiction ten years ago.
FDA approves plasmid DNA-based immunotherapy for rare viral disease www.nature.com/platform/rh/...
Inovio's doruxapapogene ralaplasmid and lalikinogene sifuplasmid for recurrent respiratory papillomatosis caused by human papillomavirus is the first plasmid DNA-based immunotherapy
Inovio's doruxapapogene ralaplasmid and lalikinogene sifuplasmid for recurrent respiratory papillomatosis caused by human papillomavirus is the first plasmid DNA-based immunotherapy
November 3, 2026 at 2:43 PM
FDA approves plasmid DNA-based immunotherapy for rare viral disease www.nature.com/platform/rh/...
Inovio's doruxapapogene ralaplasmid and lalikinogene sifuplasmid for recurrent respiratory papillomatosis caused by human papillomavirus is the first plasmid DNA-based immunotherapy
Inovio's doruxapapogene ralaplasmid and lalikinogene sifuplasmid for recurrent respiratory papillomatosis caused by human papillomavirus is the first plasmid DNA-based immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 3:27 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 3:23 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
Immunotherapy has begun, as a way to sooth progress, but it’s moved on to liver and lymph.
12 months, tops.
12 months, tops.
November 6, 2026 at 3:57 AM
Immunotherapy has begun, as a way to sooth progress, but it’s moved on to liver and lymph.
12 months, tops.
12 months, tops.
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
November 2, 2026 at 12:29 PM
Sonosensitizer-Functionalized Polymetallic Nanoenzymes for Photoacoustic Imaging-Guided Cancer Sonodynamic Immunotherapy
doi.org/10.1002/smm2...
doi.org/10.1002/smm2...
about three weeks apart. The doses aligned with their immunotherapy treatments.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
November 2, 2026 at 5:10 PM
about three weeks apart. The doses aligned with their immunotherapy treatments.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
In other words, Merck and Moderna’s personalized vaccine is designed to target the specific mutations in each patient’s tumor rather than using a one-size-fits-all approach.
Researchers said the results of the large-scale, Phase III trial, which included over 1,000 patients and expanded to Europe, has provided the real proof that personalized mRNA vaccines added to standard immunotherapy significantly reduce the risk of melanoma returning.
November 2, 2026 at 5:12 PM
Researchers said the results of the large-scale, Phase III trial, which included over 1,000 patients and expanded to Europe, has provided the real proof that personalized mRNA vaccines added to standard immunotherapy significantly reduce the risk of melanoma returning.
A three-year-old boy’s liver cancer has been in complete remission for a year after an experimental CAR-T immunotherapy. Researchers engineered the boy’s own T cells to target a protein called glypican-3 on his hepatoblastoma cells. buff.ly/pzm3veU
#ShareGoodNewsToo
#ShareGoodNewsToo
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | NEJM
A 3-year-old boy with chemotherapy-resistant metastatic hepatoblastoma had complete regression lasting at least 12 months after two infusions of glypican-3–specific CAR T cells coexpressing interle...
buff.ly
November 6, 2026 at 1:50 PM
A three-year-old boy’s liver cancer has been in complete remission for a year after an experimental CAR-T immunotherapy. Researchers engineered the boy’s own T cells to target a protein called glypican-3 on his hepatoblastoma cells. buff.ly/pzm3veU
#ShareGoodNewsToo
#ShareGoodNewsToo
